# Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia

> **NCT03624270** · PHASE2 · UNKNOWN · sponsor: **The University of Hong Kong** · enrollment: 60 (estimated)

## Conditions studied

- Acute Promyelocytic Leukemia

## Interventions

- **DRUG:** Oral arsenic Trioxide, ATRA and ascorbic acid

## Key facts

- **NCT ID:** NCT03624270
- **Lead sponsor:** The University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-08-15
- **Primary completion:** 2023-09-01
- **Final completion:** 2023-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2022-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03624270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03624270, "Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03624270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*